Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children
LGS
An Open, Multi-center, Prospective and Retrospective Observational Study to Evaluate the Long-term Safety and Effectiveness of Growth Hormone (Eutropin Inj. / Eutropin Plus Inj.) Treatment With GHD, TS, CRF, SGA, ISS and PWS in Children
1 other identifier
observational
6,000
1 country
1
Brief Summary
The purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (Eutropin Inj./Eutropin plus Inj.) treatment with GHD (Growth Hormone Deficiency), TS (Turner Syndrome),CRF (Chronic Renal Failure), SGA (Small for Gestational Age), and ISS (Idiopathic Short Stature).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2012
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2012
CompletedFirst Submitted
Initial submission to the registry
May 21, 2012
CompletedFirst Posted
Study publicly available on registry
May 23, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2032
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2032
February 21, 2021
February 1, 2021
21 years
May 21, 2012
February 17, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Safety measure : adverse event
up to 2 years after epiphyseal closure
Secondary Outcomes (3)
effectiveness measure : difference in target height and final height
up to 2 years after epiphyseal closure
effectiveness : difference in height velocity between Baseline and every year
up to 2 years after epiphyseal closure
effectiveness measure : difference in height SDS for CA between baseline and every 6 months
up to 2 years after epiphyseal closure
Study Arms (1)
growth hormone
Eligibility Criteria
children with GHD, TS, CRF, SGA and ISS
You may qualify if:
- short stature children aged 2 years or more
- children with GHD,TS, CRF, SGA or ISS
- written informed consent from the person, person's parent or legal guardian
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- LG Chemlead
Study Sites (1)
Seoul National University Hospital
Seoul, South Korea
Related Publications (5)
Kim JH, Kim SJ, Chung IH, Lim JS. Adiposity Rebound Timing in Small for Gestational Age Children Treated With Growth Hormone: Results From LG Growth Study Data. J Korean Med Sci. 2025 Feb 3;40(4):e12. doi: 10.3346/jkms.2025.40.e12.
PMID: 39901524DERIVEDJeong HR, Lee HS, Hwang JS. Growth Prediction Model for Prepubertal Children With Idiopathic Growth Hormone Deficiency: An Analysis of LG Growth Study Data. Clin Endocrinol (Oxf). 2025 Mar;102(3):281-287. doi: 10.1111/cen.15178. Epub 2024 Dec 15.
PMID: 39676465DERIVEDLee HS, Kum CD, Rho JG, Hwang JS. Long-term effectiveness of growth hormone therapy in children born small for gestational age: An analysis of LG growth study data. PLoS One. 2022 Apr 26;17(4):e0266329. doi: 10.1371/journal.pone.0266329. eCollection 2022.
PMID: 35472208DERIVEDLim HH, Kim YM, Lee GM, Yu J, Han HS, Yu J. Growth Responses During 3 Years of Growth Hormone Treatment in Children and Adolescents With Growth Hormone Deficiency: Comparison Between Idiopathic, Organic and Isolated Growth Hormone Deficiency, and Multiple Pituitary Hormone Deficiency. J Korean Med Sci. 2022 Mar 21;37(11):e90. doi: 10.3346/jkms.2022.37.e90.
PMID: 35315601DERIVEDCho WK, Ahn MB, Kim EY, Cho KS, Jung MH, Suh BK. Predicting First-Year Growth in Response to Growth Hormone Treatment in Prepubertal Korean Children with Idiopathic Growth Hormone Deficiency: Analysis of Data from the LG Growth Study Database. J Korean Med Sci. 2020 May 18;35(19):e151. doi: 10.3346/jkms.2020.35.e151.
PMID: 32419399DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
HW Chae, M.D.
Kangnam severance hospital
- PRINCIPAL INVESTIGATOR
KS Sim, M.D.
Kangdong KyungHee University hospital
- PRINCIPAL INVESTIGATOR
IT Hwang, M.D.
Kangdong Sacred Heart Hospital
- PRINCIPAL INVESTIGATOR
SC Chung, M.D.
Konkook University hospital
- PRINCIPAL INVESTIGATOR
CW Ko, M.D.
Kyungpook National University Hospital
- PRINCIPAL INVESTIGATOR
HS Kim, M.D.
Keimyung University hospital
- PRINCIPAL INVESTIGATOR
YJ Lee, M.D.
Korea University
- PRINCIPAL INVESTIGATOR
KH Lee, M.D.
Korea University Anam Hospital
- PRINCIPAL INVESTIGATOR
JH Lee, M.D.
Kosin university hospital
- PRINCIPAL INVESTIGATOR
JS Yu, M.D.
Dankook University
- PRINCIPAL INVESTIGATOR
JH Yu, M.D.
Dong-A University Hospital
- PRINCIPAL INVESTIGATOR
SY Lee, M.D.
SMG-SNU Boramae Medical Center
- PRINCIPAL INVESTIGATOR
WY Chung, M.D.
Inje University
- PRINCIPAL INVESTIGATOR
Yl Shin, M.D.
Buchun Soonchunhyang university hospital
- PRINCIPAL INVESTIGATOR
CY Kim, M.D.
daejin medical center
- PRINCIPAL INVESTIGATOR
DK Jin, M.D.
Samsung Medical Center
- PRINCIPAL INVESTIGATOR
MJ Park, M.D.
Inje University
- STUDY CHAIR
CH Shin, M.D.
Seoul National University Hospital
- PRINCIPAL INVESTIGATOR
BK Suh, M.D.
Seoul St. Mary's Hospital
- PRINCIPAL INVESTIGATOR
HW Yoo, M.D.
Asan Medical Center
- PRINCIPAL INVESTIGATOR
MH Jung, M.D.
Yeouide St. Mary's hospital
- PRINCIPAL INVESTIGATOR
SH Park, M.D.
St Vincent's Hospital
- PRINCIPAL INVESTIGATOR
DH Kim, M.D.
Sowha children's hospital
- PRINCIPAL INVESTIGATOR
DH Lee, M.D.
Seoul Soonchunhyang university hospital
- PRINCIPAL INVESTIGATOR
HS Kim, M.D.
Sinchon severance hospital
- PRINCIPAL INVESTIGATOR
JS Hwang, M.D.
Ajou University School of Medicine
- PRINCIPAL INVESTIGATOR
SY Kim, M.D.
Pusan National University Yangsan Hospital
- PRINCIPAL INVESTIGATOR
JD Kim, M.D.
Wonkwang university school of medicine & hospital
- PRINCIPAL INVESTIGATOR
HS Han, M.D.
Chungbuk National University Hospital
- PRINCIPAL INVESTIGATOR
KH Lee, M.D.
Wonkwang University Sanbon Medical Center
- PRINCIPAL INVESTIGATOR
EK Yoo, M.D.
Bunsangcha hospital
- PRINCIPAL INVESTIGATOR
BK Lim, M.D.
Wonju Christian Hospital
- PRINCIPAL INVESTIGATOR
JH Kang, M.D.
Eulji University Hospital
- PRINCIPAL INVESTIGATOR
JY Seo, M.D.
Eulji General Hospital
- PRINCIPAL INVESTIGATOR
HS Kim, M.D.
ehwa university medical center
- PRINCIPAL INVESTIGATOR
JE Lee, M.D.
Inha University Hospital
- PRINCIPAL INVESTIGATOR
JH Kim, M.D.
Inje University
- PRINCIPAL INVESTIGATOR
CJ Kim, M.D.
Chonnam National University Hospital
- PRINCIPAL INVESTIGATOR
DY Lee, M.D.
Chonbuk National University Hospital
- PRINCIPAL INVESTIGATOR
KS Shin, M.D.
Jeju National University Hospital
- PRINCIPAL INVESTIGATOR
IT Hwang, M.D.
Hallym University Medical Center
- PRINCIPAL INVESTIGATOR
SM Lee, M.D.
Hanyang University
- PRINCIPAL INVESTIGATOR
KH Lee, M.D.
Korea University Guro Hospital
- PRINCIPAL INVESTIGATOR
KS Jo, M.D.
Bucheon St. Mary's Hospital
- PRINCIPAL INVESTIGATOR
SY Ahn, M.D.
KangWon National University Hospital
- PRINCIPAL INVESTIGATOR
PS Oh, M.D.
Chuncheon Sacred Heart Hospital
- PRINCIPAL INVESTIGATOR
S Yang, M.D.
Hallym University Kangnam Sacred Heart Hospital
- PRINCIPAL INVESTIGATOR
EY Kim, M.D.
Chosun University Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 21, 2012
First Posted
May 23, 2012
Study Start
January 1, 2012
Primary Completion (Estimated)
December 31, 2032
Study Completion (Estimated)
December 31, 2032
Last Updated
February 21, 2021
Record last verified: 2021-02